Vise Technologies Inc. Takes $1.13 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Vise Technologies Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,143 shares of the biopharmaceutical company’s stock, valued at approximately $1,125,000.

Several other institutional investors and hedge funds have also modified their holdings of REGN. Nuveen LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $343,764,000. Pacer Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock worth $258,366,000 after buying an additional 390,374 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 234.7% in the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after buying an additional 326,583 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after buying an additional 174,056 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the company an “equal weight” rating in a report on Wednesday, October 29th. Sanford C. Bernstein upped their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $789.91.

Regeneron Pharmaceuticals Trading Up 2.9%

Shares of NASDAQ:REGN traded up $19.82 on Thursday, reaching $701.54. 154,953 shares of the company traded hands, compared to its average volume of 1,090,232. The stock has a market capitalization of $73.73 billion, a P/E ratio of 16.70, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The business’s 50-day simple moving average is $593.81 and its 200 day simple moving average is $569.58. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $803.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the previous year, the company posted $12.46 EPS. The firm’s revenue was up .9% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.02% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.